Top

Published in:

01-01-2011 | Introduction

Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology

Authors: Ken T. Coppieters, Bart O. Roep, Matthias G. von Herrath

Published in: Seminars in Immunopathology | Issue 1/2011

Excerpt

The fact that type 1 diabetes (T1D) is caused by an aberrant autoimmune response against beta cells has been known for almost half a century. Today, several decades after the first report on immune cells invading the pancreatic islets from recently diagnosed children [1], our knowledge on the disease’s immunopathology has dramatically improved. Yet, despite extensive research, diagnosed individuals are still condemned to a lifetime of meticulous glucose monitoring and insulin replacement therapy. A more detailed understanding of disease mechanisms is required in order to efficiently curb islet autoimmunity and ultimately design appropriate cures. Islet transplantation may serve as an example as the majority of recipients develop recurrent islet autoimmunity, indicating that simply replenishing beta cell mass is not a feasible option unless the underlying immune response is tackled [2, 3]. The aim of this special issue is to review some of the immunopathologic features that make T1D such a complex autoimmune condition. This opening chapter will provide an introduction to the topics covered by some leading specialists. …

Gepts W (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14(10):619–633PubMed

Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De Waele M, Mathieu C et al (2009) Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 58(10):2267–2276, PMCID: 2750206PubMedCrossRef

Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B et al (1999) Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 48(3):484–490PubMedCrossRef

Hanafusa T, Miyazaki A, Miyagawa J, Tamura S, Inada M, Yamada K et al (1990) Examination of islets in the pancreas biopsy specimens from newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 33(2):105–111PubMedCrossRef

Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K et al (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92(5):2313–2322, PMCID: 288412PubMedCrossRef

Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS (1986) The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29(5):267–274PubMedCrossRef

Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG (2009) Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155(2):173–181, PMCID: 2675247PubMedCrossRef

In’t Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M et al (2007) Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 56(9):2400–2404PubMedCrossRef

von Herrath M, Sanda S, Herold K (2007) Type 1 diabetes as a relapsing–remitting disease? Nat Rev Immunol 7(12):988–994CrossRef

10.

Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM et al (2010) Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 53(4):690–698PubMedCrossRef

11.

Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G et al (2010) Residual insulin production and pancreatic beta cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59(11):2846–2853PubMedCrossRef

12.

Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC (2006) Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 55(12):3238–3245PubMedCrossRef

13.

Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG (2010) Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia 53(9):2020–2028PubMedCrossRef

14.

Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M et al (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116(6):1506–1513, PMCID: 1462946PubMedCrossRef

15.

Lieberman SM, Takaki T, Han B, Santamaria P, Serreze DV, DiLorenzo TP (2004) Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol 173(11):6727–6734PubMed

16.

Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D et al (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435(7039):220–223, PMCID: 1364531PubMedCrossRef

17.

Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT et al (2003) Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 111(2):217–223, PMCID: 151866PubMed

18.

Enee E, Martinuzzi E, Blancou P, Bach JM, Mallone R, van Endert P (2008) Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J Immunol 180(8):5430–5438PubMed

19.

Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P et al (2009) Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 58(11):2588–2595, PMCID: 2768166PubMedCrossRef

20.

Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M et al (2010) Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59(7):1721–1730, PMCID: 2889772PubMedCrossRef

21.

Velthuis JH, Unger WW, van der Slik AR, Duinkerken G, Engelse M, Schaapherder AF et al (2009) Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia 52(3):494–503PubMedCrossRef

22.

Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D et al (2007) No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 56(3):604–612PubMedCrossRef

23.

Tree TI, Roep BO, Peakman M (2006) A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann NY Acad Sci 1079:9–18PubMedCrossRef

24.

Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH (2008) The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181(10):7350–7355, PMCID: 2597079PubMed

25.

Tree TI, Lawson J, Edwards H, Skowera A, Arif S, Roep BO et al (2010) Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 59(6):1451–1460, PMCID: 2874706PubMedCrossRef

26.

Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S et al (2010) IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207(9):1871–1878PubMedCrossRef

27.

Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E et al (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28(5):687–697, PMCID: 2394854PubMedCrossRef

28.

Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M et al (2009) Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10(9):1000–1007, PMCID: 2729804PubMedCrossRef

29.

Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F et al (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297(14):1568–1576PubMedCrossRef

30.

Sanda S, Roep BO, von Herrath M (2008) Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol 127(2):138–143PubMedCrossRef

31.

Kaas A, Pfleger C, Hansen L, Buschard K, Schloot NC, Roep BO et al (2010) Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis. Clin Exp Immunol 161(3):444–452PubMedCrossRef

32.

Roep BO, Peakman M (2010) Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 10(2):145–152PubMedCrossRef

33.

Tanaka S, Nishida Y, Aida K, Maruyama T, Shimada A, Suzuki M et al (2009) Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 58(10):2285–2291, PMCID: 2750208PubMedCrossRef

34.

Filippi CM, von Herrath MG (2008) Viral trigger for type 1 diabetes: pros and cons. Diabetes 57(11):2863–2871, PMCID: 2570378PubMedCrossRef

35.

Harjutsalo V, Sjoberg L, Tuomilehto J (2008) Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371(9626):1777–1782PubMedCrossRef

36.

Adams S (1926) The seasonal variation in the onset of acute diabetes. Arch Intern Med 37:861–864CrossRef

37.

Foulis AK, Farquharson MA, Meager A (1987) Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2(8573):1423–1427PubMedCrossRef

38.

Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S et al (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104(12):5115–5120, PMCID: 1829272PubMedCrossRef

39.

Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG (2009) The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia 52(6):1143–1151PubMedCrossRef

40.

Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ et al (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 38(6):617–619PubMedCrossRef

41.

Nejentsev S, Walker N, Riches D, Egholm M, Todd JA (2009) Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324(5925):387–389, PMCID: 2707798PubMedCrossRef

42.

Stene LC, Oikarinen S, Hyöty H, Barriga KJ, Norris JM, Hutton JC, Erlich HA, Eisenbarth GSR, Rewers M (2010) Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: The Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 59(12):3174–3180PubMedCrossRef

43.

Fauquet MAM CM, Maniloff J, Desselberger U, Ball LA (2005) Virus taxonomy: VIIIth report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, Burlington, MA

44.

Roivainen M (2006) Enteroviruses: new findings on the role of enteroviruses in type 1 diabetes. Int J Biochem Cell Biol 38(5–6):721–725PubMedCrossRef

45.

Filippi CM, Estes EA, Oldham JE, von Herrath MG (2009) Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest 119(6):1515–1523, PMCID: 2689128PubMed

46.

Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA et al (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23(2):115–126PubMedCrossRef

47.

Saravia-Fernandez F, Durant S, el Hasnaoui A, Dardenne M, Homo-Delarche F (1996) Environmental and experimental procedures leading to variations in the incidence of diabetes in the nonobese diabetic (NOD) mouse. Autoimmunity 24(2):113–121PubMedCrossRef

48.

Serreze DV, Wasserfall C, Ottendorfer EW, Stalvey M, Pierce MA, Gauntt C et al (2005) Diabetes acceleration or prevention by a coxsackievirus B4 infection: critical requirements for both interleukin-4 and gamma interferon. J Virol 79(2):1045–1052, PMCID: 538592PubMedCrossRef

49.

Takaki T, Marron MP, Mathews CE, Guttmann ST, Bottino R, Trucco M et al (2006) HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes. J Immunol 176(5):3257–3265PubMed

50.

Roep BO, Atkinson M, von Herrath M (2004) Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4(12):989–997PubMedCrossRef

Title: Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology
Authors: Ken T. Coppieters
Bart O. Roep
Matthias G. von Herrath
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2011
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-010-0236-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Beta cell regeneration in human pancreas

Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease

Immunopathology of the human pancreas in type-I diabetes

The pancreas in human type 1 diabetes

Enteroviruses in the pathogenesis of type 1 diabetes

Innate immunity and the pathogenesis of type 1 diabetes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials